vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and ENERGY FUELS INC (UUUU). Click either name above to swap in a different company.
ENERGY FUELS INC is the larger business by last-quarter revenue ($27.1M vs $16.1M, roughly 1.7× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -77.3%, a 69.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -32.1%). Over the past eight quarters, ENERGY FUELS INC's revenue compounded faster (98.7% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
FuelCell Energy, Inc. is a publicly traded fuel cell company headquartered in Danbury, Connecticut. It designs, manufactures, operates and services power plants based on molten carbonate fuel cells.
DERM vs UUUU — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $27.1M |
| Net Profit | $-1.2M | $-20.9M |
| Gross Margin | — | 35.0% |
| Operating Margin | -2.8% | -81.6% |
| Net Margin | -7.8% | -77.3% |
| Revenue YoY | 27.3% | -32.1% |
| Net Profit YoY | -182.0% | 36.5% |
| EPS (diluted) | $-0.04 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $27.1M | ||
| Q3 25 | $17.0M | $17.7M | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $13.1M | $16.9M | ||
| Q4 24 | $12.6M | $39.9M | ||
| Q3 24 | $14.6M | — | ||
| Q2 24 | $14.9M | $8.7M | ||
| Q1 24 | $13.0M | $25.4M |
| Q4 25 | $-1.2M | $-20.9M | ||
| Q3 25 | $-2.3M | $-16.7M | ||
| Q2 25 | $-3.8M | — | ||
| Q1 25 | $-4.1M | $-26.3M | ||
| Q4 24 | $1.5M | $-33.0M | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-3.4M | $-6.4M | ||
| Q1 24 | $-10.4M | $3.6M |
| Q4 25 | — | 35.0% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -7.3% | ||
| Q4 24 | 82.3% | 1.5% | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | 57.8% | ||
| Q1 24 | 47.7% | 56.5% |
| Q4 25 | -2.8% | -81.6% | ||
| Q3 25 | -9.0% | -150.6% | ||
| Q2 25 | -19.2% | — | ||
| Q1 25 | -25.3% | -155.0% | ||
| Q4 24 | 17.7% | -71.6% | ||
| Q3 24 | -19.8% | — | ||
| Q2 24 | -19.7% | -103.7% | ||
| Q1 24 | -77.4% | 7.9% |
| Q4 25 | -7.8% | -77.3% | ||
| Q3 25 | -13.6% | -94.5% | ||
| Q2 25 | -25.3% | — | ||
| Q1 25 | -31.0% | -155.6% | ||
| Q4 24 | 12.1% | -82.6% | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | -22.6% | -73.6% | ||
| Q1 24 | -80.1% | 14.3% |
| Q4 25 | $-0.04 | $-0.08 | ||
| Q3 25 | $-0.09 | $-0.07 | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.18 | $-0.13 | ||
| Q4 24 | $0.10 | $-0.19 | ||
| Q3 24 | $-0.12 | — | ||
| Q2 24 | $-0.17 | $-0.04 | ||
| Q1 24 | $-0.53 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $64.7M |
| Total DebtLower is stronger | $25.3M | $675.7M |
| Stockholders' EquityBook value | $31.9M | $678.4M |
| Total Assets | $94.6M | $1.4B |
| Debt / EquityLower = less leverage | 0.79× | 1.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $64.7M | ||
| Q3 25 | $24.9M | $94.0M | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | $73.0M | ||
| Q4 24 | $20.3M | $38.6M | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | $24.6M | ||
| Q1 24 | $24.1M | $54.8M |
| Q4 25 | $25.3M | $675.7M | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $678.4M | ||
| Q3 25 | $25.9M | $703.2M | ||
| Q2 25 | $19.2M | — | ||
| Q1 25 | $21.5M | $580.8M | ||
| Q4 24 | $20.1M | $527.8M | ||
| Q3 24 | $10.9M | — | ||
| Q2 24 | $11.3M | $378.8M | ||
| Q1 24 | $13.0M | $383.7M |
| Q4 25 | $94.6M | $1.4B | ||
| Q3 25 | $85.2M | $758.3M | ||
| Q2 25 | $81.2M | — | ||
| Q1 25 | $85.0M | $650.8M | ||
| Q4 24 | $80.2M | $612.0M | ||
| Q3 24 | $64.0M | — | ||
| Q2 24 | $65.2M | $403.4M | ||
| Q1 24 | $66.6M | $405.8M |
| Q4 25 | 0.79× | 1.00× | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-16.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-16.2M | ||
| Q3 25 | $-2.4M | $-28.5M | ||
| Q2 25 | $-942.0K | — | ||
| Q1 25 | $-2.8M | $-18.8M | ||
| Q4 24 | $2.2M | $-36.0M | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-5.2M | $-9.7M | ||
| Q1 24 | $-5.0M | $8.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.43× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
UUUU
Segment breakdown not available.
